Molecular basis for small molecule inhibition of G protein-coupled receptor kinases

ACS Chemical Biology

Volumn 10, Issue 1, 2015, Pages 246-256

  Homan, Kristoff T ^a   Tesmer, John J G ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; BALANOL; CHLORPROMAZINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; FASUDIL; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2 INHIBITOR; HYDROXYFASUDIL; PAROXETINE; POLYCATION; POLYLYSINE; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE INHIBITOR; RHO ASSOCIATED COILED COIL CONTAINING KINASE 1; RHO ASSOCIATED COILED COIL CONTAINING KINASE INHIBITOR; RHO KINASE; RHO KINASE INHIBITOR; SPERMIDINE; STAUROSPORINE; TAMOXIFEN; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR KINASE 2; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

CRYSTAL STRUCTURE; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; MOLECULAR LIBRARY; PHARMACOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; DRUG DISCOVERY; G-PROTEIN-COUPLED RECEPTOR KINASE 2; G-PROTEIN-COUPLED RECEPTOR KINASES; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RHO-ASSOCIATED KINASES; SMALL MOLECULE LIBRARIES;

EID: 84921357882     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb5003976     Document Type: Review

References (86)

1. Moore, N. A., Tye, N. C., Axton, M. S., and Risius, F. C. (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent J. Pharmacol. Exp. Ther. 262, 545-551
2. Tattersfield, A. E. and McNicol, M. W. (1969) Salbutamol and isoproterenol. A double-blind trial to compare bronchodilator and cardiovascular activity N. Engl. J. Med. 281, 1323-1326
3. 2 adrenergic receptor-Gs protein complex Nature 477, 549-555
4. Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K., and Stevens, R. C. (2007) High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor Science 318, 1258-1265
5. Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J., and Kobilka, B. K. (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor Nature 482, 552-556
6. Nickols, H. H. and Conn, P. J. (2014) Development of allosteric modulators of GPCRs for treatment of CNS disorders Neurobiol. Dis. 61, 55-71
7. Wisler, J. W., Xiao, K., Thomsen, A. R., and Lefkowitz, R. J. (2014) Recent developments in biased agonism Curr. Opin. Cell Biol. 27C, 18-24
8. Sjogren, B., Blazer, L. L., and Neubig, R. R. (2010) Regulators of G protein signaling proteins as targets for drug discovery Prog. Mol. Biol. Transl. Sci. 91, 81-119
9. Pearce, L. R., Komander, D., and Alessi, D. R. (2010) The nuts and bolts of AGC protein kinases Nat. Rev. Mol. Cell Biol. 11, 9-22
10. Gurevich, E. V., Tesmer, J. J., Mushegian, A., and Gurevich, V. V. (2012) G protein-coupled receptor kinases: more than just kinases and not only for GPCRs Pharmacol. Ther. 133, 40-69
11. Gurevich, V. V. and Gurevich, E. V. (2014) Extensive shape shifting underlies functional versatility of arrestins Curr. Opin. Cell Biol. 27, 1-9
12. Tilley, D. G. (2011) G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function Circ. Res. 109, 217-230
13. Lorenz, K., Lohse, M. J., and Quitterer, U. (2003) Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2 Nature 426, 574-579
14. Gainetdinov, R. R., Bohn, L. M., Walker, J. K., Laporte, S. A., Macrae, A. D., Caron, M. G., Lefkowitz, R. J., and Premont, R. T. (1999) Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice Neuron 24, 1029-1036
15. Metaye, T., Gibelin, H., Perdrisot, R., and Kraimps, J. L. (2005) Pathophysiological roles of G-protein-coupled receptor kinases Cell. Signalling 17, 917-928
16. Belmonte, S. L. and Blaxall, B. C. (2011) G protein coupled receptor kinases as therapeutic targets in cardiovascular disease Circ. Res. 109, 309-319
17. Dorn, G. W., 2nd. (2009) GRK mythology: G-protein receptor kinases in cardiovascular disease J. Mol. Med. 87, 455-463
18. Felder, R. A., Sanada, H., Xu, J., Yu, P. Y., Wang, Z., Watanabe, H., Asico, L. D., Wang, W., Zheng, S., Yamaguchi, I., Williams, S. M., Gainer, J., Brown, N. J., Hazen-Martin, D., Wong, L. J., Robillard, J. E., Carey, R. M., Eisner, G. M., and Jose, P. A. (2002) G protein-coupled receptor kinase 4 gene variants in human essential hypertension Proc. Natl. Acad. Sci. U.S.A. 99, 3872-3877
19. Gold, J. I., Gao, E., Shang, X., Premont, R. T., and Koch, W. J. (2012) Determining the absolute requirement of G protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication Circ. Res. 111, 1048-1053
20. Eschenhagen, T. (2008) β-Adrenergic signaling in heart failure-adapt or die Nat. Med. 14, 485-487
21. 1-adrenergic receptors in the failing human heart Circulation 87, 454-463
22. Ungerer, M., Parruti, G., Bohm, M., Puzicha, M., DeBlasi, A., Erdmann, E., and Lohse, M. J. (1994) Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart Circ. Res. 74, 206-213
23. Hata, J. A., Williams, M. L., and Koch, W. J. (2004) Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization J. Mol. Cell. Cardiol. 37, 11-21
24. Koch, W. J., Rockman, H. A., Samama, P., Hamilton, R. A., Bond, R. A., Milano, C. A., and Lefkowitz, R. J. (1995) Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor Science 268, 1350-1353
25. Raake, P. W., Vinge, L. E., Gao, E., Boucher, M., Rengo, G., Chen, X., DeGeorge, B. R., Jr., Matkovich, S., Houser, S. R., Most, P., Eckhart, A. D., Dorn, G. W., 2nd, and Koch, W. J. (2008) G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure Circ. Res. 103, 413-422
26. Rengo, G., Lymperopoulos, A., Zincarelli, C., Donniacuo, M., Soltys, S., Rabinowitz, J. E., and Koch, W. J. (2009) Myocardial adeno-associated virus serotype 6-βARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure Circulation 119, 89-98
27. Shah, A. S., White, D. C., Emani, S., Kypson, A. P., Lilly, R. E., Wilson, K., Glower, D. D., Lefkowitz, R. J., and Koch, W. J. (2001) In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction Circulation 103, 1311-1316
28. White, D. C., Hata, J. A., Shah, A. S., Glower, D. D., Lefkowitz, R. J., and Koch, W. J. (2000) Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction Proc. Natl. Acad. Sci. U.S.A. 97, 5428-5433
29. Laugwitz, K. L., Kronsbein, K., Schmitt, M., Hoffmann, K., Seyfarth, M., Schomig, A., and Ungerer, M. (1997) Characterization and inhibition of β-adrenergic receptor kinase in intact myocytes Cardiovasc. Res. 35, 324-333
30. Rockman, H. A., Chien, K. R., Choi, D. J., Iaccarino, G., Hunter, J. J., Ross, J., Lefkowitz, R. J., and Koch, W. J. (1998) Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice Proc. Natl. Acad. Sci. U.S.A. 95, 7000-7005
31. Raake, P. W., Schlegel, P., Ksienzyk, J., Reinkober, J., Barthelmes, J., Schinkel, S., Pleger, S., Mier, W., Haberkorn, U., Koch, W. J., Katus, H. A., Most, P., and Muller, O. J. (2013) AAV6.bARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model Eur. Heart J. 34, 1437-1447
32. Lymperopoulos, A., Rengo, G., Funakoshi, H., Eckhart, A. D., and Koch, W. J. (2007) Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure Nat. Med. 13, 315-323
33. Bastidas, A. C., Deal, M. S., Steichen, J. M., Guo, Y., Wu, J., and Taylor, S. S. (2013) Phosphoryl transfer by protein kinase A is captured in a crystal lattice J. Am. Chem. Soc. 135, 4788-4798
34. Knighton, D. R., Zheng, J. H., Ten Eyck, L. F., Ashford, V. A., Xuong, N. H., Taylor, S. S., and Sowadski, J. M. (1991) Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253, 407-414
35. Knighton, D. R., Zheng, J. H., Ten Eyck, L. F., Xuong, N. H., Taylor, S. S., and Sowadski, J. M. (1991) Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253, 414-420
36. Johnson, L. N. (2009) Protein kinase inhibitors: contributions from structure to clinical compounds Q. Rev. Biophys. 42, 1-40
37. Kannan, N., Haste, N., Taylor, S. S., and Neuwald, A. F. (2007) The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis -acting regulatory module Proc. Natl. Acad. Sci. U.S.A. 104, 1272-1277
38. Biondi, R. M., Cheung, P. C., Casamayor, A., Deak, M., Currie, R. A., and Alessi, D. R. (2000) Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA EMBO J. 19, 979-988
39. ++dependent protein kinase Biochem. Biophys. Res. Commun. 135, 397-402
40. Prade, L., Engh, R. A., Girod, A., Kinzel, V., Huber, R., and Bossemeyer, D. (1997) Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential Structure 5, 1627-1637
41. Ward, N. E. and OBrian, C. A. (1992) Kinetic analysis of protein kinase C inhibition by staurosporine: evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates Mol. Pharmacol. 41, 387-392
42. Xu, Z. B., Chaudhary, D., Olland, S., Wolfrom, S., Czerwinski, R., Malakian, K., Lin, L., Stahl, M. L., Joseph-McCarthy, D., Benander, C., Fitz, L., Greco, R., Somers, W. S., and Mosyak, L. (2004) Catalytic domain crystal structure of protein kinase C-σ (PKCσ) J. Biol. Chem. 279, 50401-50409
43. Ikuta, M., Kornienko, M., Byrne, N., Reid, J. C., Mizuarai, S., Kotani, H., and Munshi, S. K. (2007) Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: implications for the design of RSK1 specific inhibitors Protein Sci. 16, 2626-2635
44. Komander, D., Kular, G. S., Bain, J., Elliott, M., Alessi, D. R., and Van Aalten, D. M. (2003) Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition Biochem. J. 375, 255-262
45. Dong, M., Liao, J. K., Fang, F., Lee, A. P., Yan, B. P., Liu, M., and Yu, C. M. (2012) Increased Rho kinase activity in congestive heart failure Eur. J. Heart Failure 14, 965-973
46. Shi, J., Zhang, Y. W., Yang, Y., Zhang, L., and Wei, L. (2010) ROCK1 plays an essential role in the transition from cardiac hypertrophy to failure in mice J. Mol. Cell. Cardiol. 49, 819-828
47. Zhao, Z. and Rivkees, S. A. (2004) Rho-associated kinases play a role in endocardial cell differentiation and migration Dev. Biol. 275, 183-191
48. Kast, R., Schirok, H., Figueroa-Perez, S., Mittendorf, J., Gnoth, M. J., Apeler, H., Lenz, J., Franz, J. K., Knorr, A., Hutter, J., Lobell, M., Zimmermann, K., Munter, K., Augstein, K. H., Ehmke, H., and Stasch, J. P. (2007) Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase Br. J. Pharmacol. 152, 1070-1080
49. Thal, D. M., Homan, K. T., Chen, J., Wu, E. K., Hinkle, P. M., Huang, Z. M., Chuprun, J. K., Song, J., Gao, E., Cheung, J. Y., Sklar, L. A., Koch, W. J., and Tesmer, J. J. (2012) Paroxetine is a direct inhibitor of G protein-coupled receptor kinase 2 and increases myocardial contractility ACS Chem. Biol. 7, 1830-1839
50. Jacobs, M., Hayakawa, K., Swenson, L., Bellon, S., Fleming, M., Taslimi, P., and Doran, J. (2006) The structure of dimeric ROCK I reveals the mechanism for ligand selectivity J. Biol. Chem. 281, 260-268
51. Breitenlechner, C., Gassel, M., Hidaka, H., Kinzel, V., Huber, R., Engh, R. A., and Bossemeyer, D. (2003) Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity Structure 11, 1595-1607
52. Sehon, C. A., Wang, G. Z., Viet, A. Q., Goodman, K. B., Dowdell, S. E., Elkins, P. A., Semus, S. F., Evans, C., Jolivette, L. J., Kirkpatrick, R. B., Dul, E., Khandekar, S. S., Yi, T., Wright, L. L., Smith, G. K., Behm, D. J., Bentley, R., Doe, C. P., Hu, E., and Lee, D. (2008) Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases J. Med. Chem. 51, 6631-6634
53. Li, R., Martin, M. P., Liu, Y., Wang, B., Patel, R. A., Zhu, J. Y., Sun, N., Pireddu, R., Lawrence, N. J., Li, J., Haura, E. B., Sung, S. S., Guida, W. C., Schonbrunn, E., and Sebti, S. M. (2012) Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors J. Med. Chem. 55, 2474-2478
54. Patel, R. A., Forinash, K. D., Pireddu, R., Sun, Y., Sun, N., Martin, M. P., Schonbrunn, E., Lawrence, N. J., and Sebti, S. M. (2012) RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer Cancer Res. 72, 5025-5034
55. Pireddu, R., Forinash, K. D., Sun, N. N., Martin, M. P., Sung, S. S., Alexander, B., Zhu, J. Y., Guida, W. C., Schonbrunn, E., Sebti, S. M., and Lawrence, N. J. (2012) Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2) MedChemComm 3, 699-709
56. Bosanac, T., Hickey, E. R., Ginn, J., Kashem, M., Kerr, S., Kugler, S., Li, X., Olague, A., Schlyer, S., and Young, E. R. (2010) Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines Bioorg. Med. Chem. Lett. 20, 3746-3749
57. Ginn, J. D., Bosanac, T., Chen, R., Cywin, C., Hickey, E., Kashem, M., Kerr, S., Kugler, S., Li, X., Prokopowicz, A., 3rd, Schlyer, S., Smith, J. D., Turner, M. R., Wu, F., and Young, E. R. (2010) Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive rats Bioorg. Med. Chem. Lett. 20, 5153-5156
58. Benovic, J. L., Stone, W. C., Caron, M. G., and Lefkowitz, R. J. (1989) Inhibition of the β-adrenergic receptor kinase by polyanions J. Biol. Chem. 264, 6707-6710
59. Lodowski, D. T., Pitcher, J. A., Capel, W. D., Lefkowitz, R. J., and Tesmer, J. J. (2003) Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gbg Science 300, 1256-1262
60. Benovic, J. L., Onorato, J., Lohse, M. J., Dohlman, H. G., Staniszewski, C., Caron, M. G., and Lefkowitz, R. J. (1990) Synthetic peptides of the hamster β 2-adrenoceptor as substrates and inhibitors of the β-adrenoceptor kinase Br. J. Clin. Pharmacol. 30, 3S-12S
61. Winstel, R., Ihlenfeldt, H. G., Jung, G., Krasel, C., and Lohse, M. J. (2005) Peptide inhibitors of G protein-coupled receptor kinases Biochem. Pharmacol. 70, 1001-1008
62. Quitterer, U., Pohl, A., Langer, A., Koller, S., and Abdalla, S. (2011) A cleavable signal peptide enhances cell surface delivery and heterodimerization of Cerulean-tagged angiotensin II AT1 and bradykinin B2 receptor Biochem. Biophys. Res. Commun. 409, 544-549
63. Fu, X., Koller, S., Abd Alla, J., and Quitterer, U. (2013) Inhibition of G-protein-coupled receptor kinase 2 (GRK2) triggers the growth-promoting mitogen-activated protein kinase (MAPK) pathway J. Biol. Chem. 288, 7738-7755
64. Baameur, F., Hammitt, R. A., Friedman, J., McMurray, J. S., and Clark, R. B. (2014) Biochemical and cellular specificity of peptide inhibitors of G protein-coupled receptor kinases Int. J. Pept. Res. Ther. 20, 1-12
65. Baameur, F., Morgan, D. H., Yao, H., Tran, T. M., Hammitt, R. A., Sabui, S., McMurray, J. S., Lichtarge, O., and Clark, R. B. (2010) Role for the regulator of G-protein signaling homology domain of G protein-coupled receptor kinases 5 and 6 in β 2-adrenergic receptor and rhodopsin phosphorylation Mol. Pharmacol. 77, 405-415
66. Mayer, G., Wulffen, B., Huber, C., Brockmann, J., Flicke, B., Neumann, L., Hafenbradl, D., Klebl, B. M., Lohse, M. J., Krasel, C., and Blind, M. (2008) An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro RNA 14, 524-534
67. Tesmer, V. M., Lennarz, S., Mayer, G., and Tesmer, J. J. (2012) Molecular mechanism for inhibition of G protein-coupled receptor kinase 2 by a selective RNA aptamer Structure 20, 1300-1309
68. Kassack, M. U., Hogger, P., Gschwend, D. A., Kameyama, K., Haga, T., Graul, R. C., and Sadee, W. (2000) Molecular modeling of G-protein coupled receptor kinase 2: docking and biochemical evaluation of inhibitors AAPS PharmSci 2, E2
69. Iino, M., Furugori, T., Mori, T., Moriyama, S., Fukuzawa, A., and Shibano, T. (2002) Rational design and evaluation of new lead compound structures for selective βARK1 inhibitors J. Med. Chem. 45, 2150-2159
70. Cho, S. Y., Lee, B. H., Jung, H., Yun, C. S., Ha, J. D., Kim, H. R., Chae, C. H., Lee, J. H., Seo, H. W., and Oh, K. S. (2013) Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors Bioorg. Med. Chem. Lett. 23, 6711-6716
71. Palczewski, K., Kahn, N., and Hargrave, P. A. (1990) Nucleoside inhibitors of rhodopsin kinase Biochemistry 29, 6276-6282
72. Loomis, C. R. and Bell, R. M. (1988) Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C J. Biol. Chem. 263, 1682-1692
73. Osada, H., Sonoda, T., Tsunoda, K., and Isono, K. (1989) A new biological role of sangivamycin; inhibition of protein kinases J. Antibiot. 42, 102-106
74. Boguth, C. A., Singh, P., Huang, C. C., and Tesmer, J. J. (2010) Molecular basis for activation of G protein-coupled receptor kinases EMBO J. 29, 3249-3259
75. Kulanthaivel, P., Hallock, Y. F., Boros, C., Hamilton, S. M., Janzen, W. P., Ballas, L. M., Loomis, C. R., Jiang, J. B., Katz, B., Steiner, J. R., and Clardy, J. (1993) Balanol-a novel and potent inhibitor of protein-kinase-C from the fungus Verticillium balanoides J. Am. Chem. Soc. 115, 6452-6453
76. Setyawan, J., Koide, K., Diller, T. C., Bunnage, M. E., Taylor, S. S., Nicolaou, K. C., and Brunton, L. L. (1999) Inhibition of protein kinases by balanol: specificity within the serine/threonine protein kinase subfamily Mol. Pharmacol. 56, 370-376
77. Tesmer, J. J., Tesmer, V. M., Lodowski, D. T., Steinhagen, H., and Huber, J. (2010) Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol J. Med. Chem. 53, 1867-1870
78. Narayana, N., Diller, T. C., Koide, K., Bunnage, M. E., Nicolaou, K. C., Brunton, L. L., Xuong, N. H., Ten Eyck, L. F., and Taylor, S. S. (1999) Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase Biochemistry 38, 2367-2376
79. Takeda Pharmaceutical Company Ltd., Ikeda, S., Keneko, M., and Fujiwara, S. (2007) Cardiotonic agent comprising GRK inhibitor. World Patent WO2007034846, March 29.
80. Thal, D. M., Yeow, R. Y., Schoenau, C., Huber, J., and Tesmer, J. J. (2011) Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors Mol. Pharmacol. 80, 294-303
81. Edwards, B. S., Zhu, J., Chen, J., Carter, M. B., Thal, D. M., Tesmer, J. J., Graves, S. W., and Sklar, L. A. (2012) Cluster cytometry for high-capacity bioanalysis Cytometry, Part A 81, 419-429
82. Homan, K. T., Wu, E., Wilson, M. W., Singh, P., Larsen, S. D., and Tesmer, J. J. (2014) Structural and functional analysis of G protein-coupled receptor kinase inhibition by paroxetine and a rationally designed analog Mol. Pharmacol. 85, 237-248
83. Clarke, M. and Dodson, P. M. (2007) PKC inhibition and diabetic microvascular complications Best Pract. Res., Clin. Endocrinol. Metab. 21, 573-586
84. Akamine, P., Madhusudan, Brunton, L. L., Ou, H. D., Canaves, J. M., Xuong, N. H., and Taylor, S. S. (2004) Balanol analogues probe specificity determinants and the conformational malleability of the cyclic 3′,5′-adenosine monophosphate-dependent protein kinase catalytic subunit Biochemistry 43, 85-96
85. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G., McCoy, A., McNicholas, S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A., and Wilson, K. S. (2011) Overview of the CCP4 suite and current developments Acta Crystallogr., Sect. D: Biol. Crystallogr. 67, 235-242
86. Anand, G., Taylor, S. S., and Johnson, D. A. (2007) Cyclic-AMP and pseudosubstrate effects on type-I A-kinase regulatory and catalytic subunit binding kinetics Biochemistry 46, 9283-9291